Towa Pharmaceutical Co., Ltd. TSE:4553
Towa Pharmaceutical : FY2025(1st quarter) Supplementary Material of Financial Results(922K／23P)
Source: MarketScreener
2025
Notes to financial results disclosure material Notes
In this document, for the breakdown of the domestic segment,
Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, and Kyushu Iyaku are referred to as "Towa Pharmaceutical, etc.," and Sunsho Pharmaceutical and Sun Freres Lab. are referred to as "Sunsho Pharmaceutical, etc."
On April 1, 2025, the Company carried out an absorption-type merger with Sunsho Pharmaceutical as the surviving company and KAMATA as the disappearing company.
Towa Pharma International Holdings, S.L., our overseas segment, is referred to as "Towa INT."
"Towa Pharmaceutical, etc." "Sunsho Pharmaceutical, etc." "Towa INT"
Towa Pharmaceutical
J-Dolph Pharmaceutical
Daichi Kasei
Greencaps Pharmaceutical
Kyushu Iyaku
Sunsho Pharmaceutical
Towa Pharma International Holdings
Sun Freres Lab.
Towa Pharma Europe
Breckenridge Pharmaceutical
Towa Pharmaceutical
2025 1
Table of contents
- Outline of financial results for 2026/3 1Q
- Reference materials
2025 2
Table of contents
- Outline of financial results for 2026/3 1Q
Reference materials
2025 3
Summary of financial results for 2026/3 1Q
-
YoY change: Net sales increased, but profit decreased on a consolidated basis
Net sales and gross profit increased due to an increase in supply to the market following an increase in production volume at Towa Pharmaceutical.
Operating profit decreased due to the poor performance of Sunsho Pharmaceutical and Towa INT.
Ordinary profit decreased due to the posting of a 1.4 billion yen loss on valuation of derivatives as well as the decrease in operating profit. In 25/3 1Q, a 2.2 billion yen gain on valuation of derivatives was recognized.
- Progress rate for the full-year plan: Net sales: 23.3%, Operating profit: 19.3% on a consolidated basis
Net sales were almost as planned.
The progress rate for gross profit and operating profit were not good due to a rise in the cost of sales ratio at Sunsho Pharmaceutical and Towa INT.
The progress rate for ordinary profit was not good due to the posting of an unplanned 1.4 billion yen loss on valuation of derivatives. Due to uncertainty in exchange rate trends, etc., we have not revised the full-year plan.
(The plan does not include any gain or loss on valuation of derivatives.)
26/3 1Q results | 25/3 1Q results | 26/3 1H plan | 26/3 full-year plan | ||||
(JPY billion) | YOY change (%) | (JPY billion) | (JPY billion) | Progress rate (%) | (JPY billion) | Progress rate (%) | |
Net sales | 65.1 | 4.1% | 62.5 | 134.5 | 48.4% | 280.0 | 23.3% |
Gross profit | 23.6 | 1.4% | 23.3 | 50.1 | 47.3% | 104.0 | 22.8% |
Operating profit | 5.2 | - 8.2% | 5.6 | 12.0 | 43.4% | 27.0 | 19.3% |
Ordinary profit | 3.9 | - 54.0% | 8.5 | 11.1 | 35.6% | 25.3 | 15.6% |
Profit attributable to owners of parent | 2.5 | - 54.3% | 5.4 | 8.0 | 31.4% | 17.7 | 14.2% |
Exchange rate at end of period (TTM) USD 1 | 26/3 1Q | 25/3 4Q | 25/3 1Q | 24/3 4Q |
JPY 144.81 | JPY 149.52 | JPY 161.07 | JPY 151.41 |
2025 4